$25.630
-0.728 (-2.84%)收盘时
CAI 资讯
CAI 事件
Caris Life Sciences Sees 2026 Revenue of $1.03B-$1.04B
Caris Life Sciences sees 2026 revenue $1.03B-$1.04B, consensus $"This was a reco
Caris Reports Q2 Revenue of $263.7M, Exceeding Expectations
Reports Q2 revenue $263.7M, consensus $238.08M. "This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine," said David Dean Halbert, CEO. "Our comprehensive approach gives every case real molecular depth, across more than 1.13 million patients with AI trained on it, that depth is what powers Caris Detect. And Detect doesn't stop at finding cancer early, through what we call the Mutational Cleanse, we plan to turn an early signal into personalized immune targets, moving from early detection to early interception. It all comes back to one thing: making precision medicine a reality for every patient."
Caris Life Sciences Launches PTEN IHC Testing
Caris Life Sciences will offer in-house PTEN immunohistochemistry, or IHC, testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naive or -sensitive - mAPMN/S - prostate cancer, who are eligible for the newly approved biomarker-guided therapy. The FDA approval of capivasertib, in combination with abiraterone and prednisone, for adults with PTEN-deficient mAPMN/S prostate cancer marks a critical turning point for this disease, enabling a more personalized approach to treatment. Caris' PTEN IHC testing expands the company's already extensive menu of IHC assays and will enable oncologists to identify patients whose tumors exhibit PTEN protein loss.
Illumina Appoints Mike Sullivan as Chief Commercial Officer
Illumina (ILMN) announced the appointment of Mike Sullivan as Chief Commercial Officer, CCO, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, CLO, effective August 3, 2026. Most recently, Sullivan served as Chief Commercial Officer at Caris Life Sciences (CAI). Previously, Coletti served as Chief Legal and Regulatory Officer at Align Technology.
Caris Life Sciences Launches Multi-Cancer Early Detection Blood Test
Caris Life Sciences announced the commercial launch of Caris Detect, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages. Caris Detect is engineered to push the boundaries of what is possible in early cancer detection. Using ultra-deep Whole Genome Sequencing, Whole Transcriptome Sequencing and advanced artificial intelligence, the test analyzes a broad spectrum of molecular and biological signals associated with cancer, offering a more comprehensive approach than technologies that rely on limited genomic snapshots. Caris Detect's intended goal is to replace other outdated screening methods as the new standard of care for early detection of cancer. Caris Detect is powered by Caris' expansive molecular profiling database, which includes more than one million cases and over 50B molecular markers. This unparalleled dataset enables highly sophisticated AI models to detect subtle signals associated with early-stage disease across multiple cancer types.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。